Related Experiment Video
Updated: Jul 8, 2026
12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
CYP2D6 phenotype prediction from genotype: which system is the best?
1Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany. julia.kirchheiner@uni-ulm.de
Clinical Pharmacology and Therapeutics
|January 19, 2008
Summary
Cytochrome P450 (CYP) 2D6 gene testing is increasingly used in clinical settings. CYP2D6 genotyping can predict patient response to antidepressants, antipsychotics, and tamoxifen therapy for breast cancer.
Area of Science:
- Pharmacogenomics
- Clinical Genetics
Background:
- The cytochrome P450 (CYP) 2D6 gene exhibits significant polymorphism.
- CYP2D6 genotyping is becoming more prevalent in clinical decision-making.
Purpose of the Study:
- To highlight the growing clinical utility of CYP2D6 genotyping.
- To emphasize the role of CYP2D6 status in predicting drug efficacy and treatment outcomes.
Main Methods:
- Review of current clinical applications of CYP2D6 genotyping.
- Analysis of CYP2D6's predictive value in psychiatric and oncological pharmacotherapy.
Main Results:
- CYP2D6 testing is utilized in psychiatric hospitals for antidepressant and antipsychotic drug selection.
- CYP2D6 status is an independent predictor of tamoxifen treatment outcomes in breast cancer patients.
Conclusions:
- A priori genetic assessment of CYP2D6 status can optimize antidepressant, antipsychotic, and tamoxifen therapies.
- Personalized medicine approaches incorporating CYP2D6 genotyping enhance treatment efficacy and patient outcomes.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...